Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA sitewide NIH notice about using “Super Intelligence” in place of “Artificial Intelligence” appears above the page, which still displays a 403 error. The site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe site’s footer revision changed from v3.7.0 to v3.7.1, and a feedback tab is visible along the page edge.SummaryDifference0.2%

- Check40 days agoChange DetectedThe study record page now displays a 403 Forbidden error page with a Home link, replacing the usual content and preventing access to the trial's details. This change removes the expected study information from the page and directs users to the site’s home page instead.SummaryDifference22%

- Check47 days agoChange DetectedA new site revision label, v3.7.0, was added while the previous label, v3.6.6, was removed, indicating an internal build update rather than changes to the study record.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous v3.6.5. This indicates a maintenance/update to the page's underlying system rather than changes to the study content.SummaryDifference0.0%

- Check68 days agoChange DetectedA 2023 U.S. NIH Grant/Contract funding line was added to the study's funding disclosures, updating the source of support for the trial.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.